Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Pipeline Review, H2 2016’, provides in depth analysis on Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Advinus Therapeutics Ltd

Amgen Inc.

Hua Medicine (Shanghai) Ltd.

LG Life Science LTD.

Ligand Pharmaceuticals, Inc.

Novartis AG

Poxel SA

Takeda Pharmaceutical Company Limited

Teijin Pharma Limited

vTv Therapeutics Inc

Yuhan Corporation

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) Overview 7

Therapeutics Development 8

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Products under Development by Stage of Development 8

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Products under Development by Therapy Area 9

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Products under Development by Indication 10

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Products under Development by Companies 13

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 17

Assessment by Molecule Type 18

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Companies Involved in Therapeutics Development 19

Advinus Therapeutics Ltd 19

Amgen Inc. 20

Hua Medicine (Shanghai) Ltd. 21

LG Life Science LTD. 22

Ligand Pharmaceuticals, Inc. 23

Novartis AG 24

Poxel SA 25

Takeda Pharmaceutical Company Limited 26

Teijin Pharma Limited 27

vTv Therapeutics Inc 28

Yuhan Corporation 29

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Drug Profiles 30

AM-9514 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

GKM-001 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

LC-280391 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

LCZ-960 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Sinogliatin - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

TMG-123 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

TTP-399 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

YH-GKA - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Dormant Projects 45

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Discontinued Products 46

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Featured News & Press Releases 47

Oct 17, 2016: Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug 47

Aug 10, 2016: vTv Therapeutics Announces Positive Topline Results from Phase 2B Study of Glucokinase Activator TTP399 in Type 2 Diabetes 48

Jun 14, 2016: vTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions 48

Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity 49

Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes 49

Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial 50

Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes 51

Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug 51

Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control 52

Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics 53

Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients 55

Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial 56

Nov 29, 2012: Hua Medicine's Glucokinase Activator Passes Provincial FDA Inspections, Phase I Trial Likely To Be Launched In 2013 56

Nov 23, 2012: Hua Medicine Advances Diabetic Drug Towards Trial 57

Nov 29, 2011: Advinus's Glucokinase Activator Achieves Early POC For Diabetes 57

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Advinus Therapeutics Ltd, H2 2016 19

Pipeline by Amgen Inc., H2 2016 20

Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 21

Pipeline by LG Life Science LTD., H2 2016 22

Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 23

Pipeline by Novartis AG, H2 2016 24

Pipeline by Poxel SA, H2 2016 25

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 26

Pipeline by Teijin Pharma Limited, H2 2016 27

Pipeline by vTv Therapeutics Inc, H2 2016 28

Pipeline by Yuhan Corporation, H2 2016 29

Dormant Projects, H2 2016 45

Discontinued Products, H2 2016 46

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports